Previous 10 | Next 10 |
Like many companies, Fulgent Genetics (NASDAQ: FLGT) has been labeled a "pandemic stock" by some investors. It's easy to understand why. In the most recent quarter, 82% of Fulgent's revenue came from COVID-19 tests. However, buried beneath this headline statistic is a genetic testin...
Although cases of COVID-19 in the U.S. have fallen to less than half of their numbers just two months ago, it's looking increasingly likely that there will be a long tail of demand for vaccines, boosters, and testing. Despite that, the market seems to be losing interest in COVID stocks ...
Fulgent Genetics (NASDAQ: FLGT) announced its third-quarter results on Nov. 9, 2021. In this Motley Fool Live video recorded on Nov. 10 , Motley Fool contributors Keith Speights and Brian Orelli discuss what investors should like about the company's Q3 update. ...
Fulgent has benefited tremendously from its COVID-19 testing business. As we move towards an endemic COVID era, questions on Fulgent's core NGS business starts emerging. We discuss what investors should consider on Fulgent stock moving forward. For further details see: F...
Investors worry about the demise of their insanely profitable Covid business, but they shouldn't. The epic ramp in that business put the company on the map and will deliver $1B+ in cash by the end of the year. They are using that bonanza wisely to accelerate their core NGS busines...
Image source: The Motley Fool. Fulgent Genetics, Inc. Common Stock (NASDAQ: FLGT) Q3 2021 Earnings Call Nov 09, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Fulgent Genetics, Inc. Common Stock (FLGT) Q3 2021 Earn...
Fulgent Genetics, Inc. (FLGT) Q3 2021 Earnings Conference Call November 9, 2021, 4:30 PM ET Company Participants Ming Hsieh – Chief Executive Officer Nicole Borsje – Investor Relations Paul Kim – Chief Financial Officer Larry Weiss – Chief Medical Officer Brandon P...
Fulgent Genetics (NASDAQ:FLGT): Q3 Non-GAAP EPS of $4.05 beats by $0.80; GAAP EPS of $3.93 beats by $2.36. Revenue of $227.87M (+124.0% Y/Y) beats by $20.82M. Press Release Q4 2021 Outlook: Total Revenue of approximately $189 million, Core Revenue of approximately $32 million, representing gr...
Revenue grows 124% year-over-year to $227.9 million Core Revenue grows 292% year-over-year to $40.1 million Raises Full Year Revenue guidance to $930 million from $800 million, given recent strength in core and COVID-19 business Fulgent Genetics, Inc. (NASDAQ: FLGT) ...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of it...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2024 financial results be...
2024-07-01 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...